Table 1 Demographic features and ongoing treatment of CAPS patients

From: Progressive waves of IL-1β release by primary human monocytes via sequential activation of vesicular and gasdermin D-mediated secretory pathways

Patients

Sex

NLRP3 mutation

Disease onset

Age (years)

Treatment

1

M

T348M

6 months

30,2

Canakinumab 300 mg every 4 weeks

2

F

E525K

15 months

24

Canakinumab 150 mg every 8 weeks

3

M

M406I

Birth

15,75

Canakinumab 4 mg/kg every 4 weeks

4

F

E567K

Birth

6,9

Anakinra 7 mg/kg/day

5

M

D303N

2 weeks

2,9

Anakinra 2 mg/kg/day

Back to article page